缬沙坦治疗慢性心功能不全合并阵发性房颤的临床疗效

目的 探讨缬沙坦在慢性心功能不全合并阵发性房颤中的临床疗效。方法 选取2017年1月~2019年1月我院收治的慢性心功能不全合并阵发性房颤患者120例，按照随机数字表法分为对照组和研究组，各60例。对照组给予胺碘酮片口服治疗，研究组在对照组基础上加用缬沙坦进行治疗，比较两组治疗前后血浆肾素（PRA）、血管紧张素Ⅱ（AngⅡ）、脑钠肽（BNP）、超敏C反应蛋白（hs-CRP）水平、心功能指标与临床疗效。结果 治疗前两组PRA、AngⅡ、BNP及hs-CPR水平比较，差异无统计学意义（P＞0.05）；治疗后，研究组PRA、AngⅡ、BNP及hs-CPR水平低于对照组，差异有统计学意义（P＜0.05）。治疗前两组LEVF、LEVDD及LEVSD比较，差异无统计学意义（P＞0.05）；治疗后，研究组LEVF高于对照组，LEVDD与LEVSD低于对照组，差异有统计学意义（P＜0.05）。研究组临床治疗总有效率为88.33%，高于对照组的68.33%，差异有统计学意义（P＜0.05）。结论缬沙坦治疗慢性心功能不全合并阵发性房颤疗效显著，可有效改善心功能、抑制房颤发作，具有较高的临床应用价值。

Clinical Efficacy of Valsartan in the Treatment of Chronic Heart Failure Complicated withParoxysmal Atrial Fibrillation

Abstract:Objective To investigate the clinical efficacy of valsartan in patients with chronic heart failure and paroxysmal atrial fibrillation. Methods A total of 120 patients with chronic cardiac insufficiency and paroxysmal atrial fibrillation admitted to our hospital from January 2017 to January 2019 were enrolled. The patients were divided into the control group and the study group according to the random number table method, 60 cases each. The control group was treated with amiodarone tablets orally. The study group was treated with valsartan on the basis of the control group. Plasma renin (PRA), angiotensin II (Ang II) and brain natriuretic peptide (BNP) were compared before and after treatment, high-sensitivity C-reactive protein (hs-CRP) levels, cardiac function indicators and clinical efficacy. Results There were no significant differences in the levels of PRA, AngII, BNP and hs-CPR between the two groups before treatment (P>0.05). After treatment, the levels of PRA, AngII, BNP and hs-CPR in the study group were lower than those in the control group,the difference was statistically significant (P<0.05). There was no significant difference in LEVF, LEVDD and LEVSD between the two groups before treatment (P>0.05). After treatment, the LEVF of the study group was higher than that of the control group, LEVDD and LEVSD were lower than the control group, the difference was statistically significant (P<0.05). The total effective rate of clinical treatment in the study group was 88.33%, which was higher than that of the control group 68.33%,the difference was statistically significant (P<0.05). Conclusion Valsartan has significant curative effect on chronic heart failure combined with paroxysmal atrial fibrillation, which can effectively improve cardiac function and inhibit the onset of atrial fibrillation. It has high clinical value.